PANEL ORGANIZER and MODERATOR

Ananta Addala, DO, MPH
Assistant Professor, Stanford University, USA

Professor Ananta Addala is a pediatric endocrinologist and physician scientist at Stanford University addressing disparities in pediatric type 1 diabetes management and outcomes. As a physician with a background in pediatric endocrinology, epidemiology, and behavioral health, she aims to build an evidence-based approach to addressing T1D disparities by systematically evaluating youth-, family-, provider-, and system-level barriers to optimal diabetes care in youth from low socioeconomic and racial/ethnic minority groups. She is funded by NIDDK K23 to understand and address disparities in pediatric diabetes technology access and utilization. She also has funding from the Maternal Child Research Institute and Helmsley Charitable Trust. To date, her publications have demonstrated that the disparities in pediatric T1D by socioeconomic status are worsening in the US, provider bias against public insurance is common, and public insurance mediated interruptions to diabetes technology adversely impact glycemic outcomes. She has also been leading the efforts to improve justice, equity, diversity, and inclusion in research at Stanford University through her leadership at Stanford Pediatrics Advancing Anti-Racism Coalition and as the co-chair of TrialNet's Underrepresented Minorities Outreach Committee.

Clinical Assistant Professor, Deputy Medical Director, Department of Medicine and Therapeutics,
Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong SAR 

Professor Elaine Chow received her medical training in the UK and completed her PhD on cardiovascular effects of hypoglycaemia with Prof. Simon Heller at University of Sheffield in 2015. She has since joined the Chinese University of Hong Kong with Prof Juliana Chan and her group, where she helped set up glucose clamp and sensor evaluation studies at the Phase 1 Clinical Trial Center. She secured a number of external grants, and currently leads clinical trials on use of CGM in prediabetes, advanced chronic kidney disease, and peritoneal dialysis. In particular, she is interested in the use of CGM to evaluate basal insulins as well as other drug and non-drug interventions. She has been principal investigator or co-investigator for over 70 Phase 1 to 4 studies relating to cardiometabolic drugs. She has published over 100 peer-reviewed articles, including articles in Diabetes Care, Diabetes, and Nature Reviews Endocrinology. She has also received several awards, including the Hong Kong College of Physicians Richard Yu Lecture and Women’s Interprofessional Network of the American Diabetes Association abstract award in 2022. In addition to teaching and research, she is associate editor and editorial board member for several journals.

Associate Professor, University of Nottingham
Honorary Consultant Diabetologist, University Hospitals of Derby and Burton NHS FT
Founder, Diabetes Technology Network UK

Emma Wilmot is an Associate Professor at the University of Nottingham, Consultant Diabetologist in Derby, and founder of the Diabetes Technology Network UK. She has over 100 publications and has been principal or chief investigator on a range of diabetes studies. She was previously awarded the University of Leicester medal for excellent PhD performance “Type 2 diabetes in younger adults”. As founder of the award-winning Association of British Clinical Diabetologists (ABCD) Diabetes Technology Network UK, she led the organisation to support improvements in access to diabetes technology in the UK, developing and delivering policies and educational resources for both health care professionals and people living with diabetes. Emma is an ABCD committee member, deputy lead for the ABCD audit programme and ABCD academic sub-committee member. She is also a DAFNE structured education executive board member and expert advisor for the National Diabetes Audit programme. Emma is regularly invited to deliver national and international lectures.